There is a useful way to understand Bayer, the 163-year-old German life-sciences company: picture three clocks mounted on the same wall. The first ticks in decades, measuring the patient accumulation of molecular research, clinical trials and regulatory review. The second turns with the crop year, from seed selection through harvest. The third runs by the hour, whenever somebody reaches for allergy relief, skin cream or an aspirin. Bayer has to keep all three on time.
That explains both the company's reach and its management headache. Bayer is not simply a pharmaceutical manufacturer with a side business. Its three divisions - Pharmaceuticals, Consumer Health and Crop Science - address distinct buyers, regulations and economics. Together they generated €45.6 billion in 2025 sales, supported by roughly 88,000 employees in more than 80 countries. The portfolio moves from prescription oncology drugs to corn genetics to products sold beside toothpaste.
Drug discovery
Crop science
Self-care
One premise beneath the sprawl
The connecting idea is biology translated into useful products. In medicine, Bayer studies a pathway, develops a therapy, proves its effect and builds the manufacturing and access system around it. In agriculture, the object may be a seed trait, a new herbicide mode of action or a microbial product. In consumer health, the scientific novelty is often less dramatic, but formulation, trust, packaging and distribution determine whether a remedy earns a permanent place in the cabinet.
Its customers rarely meet. A cardiologist prescribing Kerendia for chronic kidney disease does not shop like a soybean farmer choosing DEKALB seed and crop protection. A radiology department buying contrast media does not behave like a parent buying Claritin. Bayer reaches these groups through hospitals, physicians, pharmacies, retailers, agricultural distributors, seed dealers and digital platforms. That breadth gives it many doors into health and food systems. It also makes a simple company story nearly impossible.
What the company actually sells
Pharmaceuticals focuses on cardiology and kidney disease, oncology, women's health, hematology and ophthalmology. Its established products include Xarelto, Eylea, Nubeqa, Mirena and Adempas. Newer growth rests on medicines such as Kerendia, the prostate-cancer treatment Nubeqa and Lynkuet, a hormone-free treatment for moderate to severe menopausal hot flashes. Bayer also sells radiology contrast agents, injection systems and software, giving it a foothold in the diagnostic work that precedes treatment.
Consumer Health is the familiar shelf. Aspirin, Bepanthen, Claritin and Elevit sit inside a portfolio of more than 150 brands spanning pain, allergies, dermatology, digestion and nutrition. These products solve ordinary, frequent problems without requiring the economics of a patented specialty drug. The model depends on brand memory, retail presence, formulation improvements and the slow conversion of suitable prescription ingredients to nonprescription status.
Crop Science is closer to a system than a catalog. It sells high-value seed, biotechnology traits, herbicides, fungicides, insecticides and biological crop protection. FieldView adds farm data and digital decision support; satellite imagery from Planet Labs sharpens in-season crop monitoring. The PRECEON Smart Corn System uses shorter plants designed for better standability and field access. These parts can reinforce one another: genetics sets the crop's potential, protection defends it and software helps decide what to do next.
The problems are concrete even when the portfolio looks abstract. Patients need treatments for chronic and difficult disease. Health systems need diagnosis and prevention that reduce later strain. Consumers need affordable ways to handle minor ailments themselves. Farmers need to protect yield while weather, resistance and input costs keep changing. In 2025, Bayer said its access programs reached 82 million people in underserved communities with self-care, 68 million women in lower-income countries with modern contraception and 53 million smallholder farmers with products and services. Those figures are not the same as commercial customers, but they show the scale at which the mission is meant to operate.
“Health for all, Hunger for none” is expansive enough to fit a drug pipeline and a cornfield. Execution lives in the distance between them.Bayer's mission, tested by the portfolio
The bundle is the difference
No single Bayer division lacks rivals. Roche, Novartis, Pfizer, AstraZeneca, Merck and Sanofi compete for pharmaceutical science and market share. Haleon, Kenvue, Procter & Gamble and Reckitt fight for the self-care shelf. Corteva, Syngenta, BASF and FMC meet Bayer in agricultural inputs. Specialist software and equipment companies contest digital farming.
Bayer's distinction is the combination of research scale, regulatory experience, brands and routes to market across human and plant biology. It spent €5.8 billion on R&D in 2025 and employs about 15,000 people in research. Its Crop Science compound library alone holds roughly 2.5 million substances. Few competitors can put that scientific machinery behind a product set ranging from a targeted cancer drug to hybrid wheat.
Partnerships widen the aperture. Microsoft has helped build cloud and generative-AI tools for agriculture. Ginkgo Bioworks works with Bayer on microbes that could help crops fix nitrogen. Pairwise brings genome-editing tools. In June 2026, Bayer began working with Iambic on AI-led small-molecule discovery. The following month it expanded its RAGT agreement to target broad hybrid-wheat commercialization in Europe and North America in the early 2030s. The company is effectively buying speed, specialist knowledge or optionality where internal research is not enough.
A business model with expensive patience
Bayer makes money from products protected in different ways. Prescription drugs can command premium pricing during patent exclusivity, but their discovery costs are high and failure is common. Consumer brands use recognition and distribution to create repeat purchases. Seeds and traits combine seasonal sales with intellectual property and local agronomic service. Crop-protection products need regulatory approvals and continued stewardship. Radiology mixes equipment, software and consumables. FieldView adds a digital relationship that can persist between purchases.
The common requirement is patient capital. A medicine can take more than a decade to reach patients. A new crop trait must survive breeding, field testing and approvals across markets. Even a familiar consumer brand needs manufacturing quality and retailer confidence every week. Bayer's scale can fund those waits and spread risk. But scale also creates layers, and layers slow decisions. That is why its internal redesign matters as much as any laboratory result.
The turnaround inside the turnaround
Chief Executive Bill Anderson has pushed an operating model called Dynamic Shared Ownership. The language sounds abstract; the practical intent is clear. Smaller teams receive more authority, management layers shrink and accountability moves closer to patients, consumers and farmers. Bayer expects the redesign to contribute €2 billion in savings. More important, it is meant to help a large company act before another product clock gets away from it.
The work happens under pressure. The 2018 Monsanto acquisition made Bayer a leading integrated agriculture player, but Roundup litigation became a costly and persistent overhang. Debt limits room for error. In 2025, litigation-related special charges contributed to a €3.62 billion net loss, even as sales reached €45.575 billion and net financial debt declined to €29.843 billion at year end. Bayer's current priorities pair pipeline renewal and Crop Science profitability with balance-sheet repair and litigation containment.
Recent moves show the portfolio and the financial architecture changing together. Bayer completed its acquisition of Perfuse Therapeutics in June 2026, adding the Phase II ophthalmology asset PER-001 for glaucoma and diabetic retinopathy. The deal included $300 million upfront and could reach $2.45 billion with milestones. In July, Apollo agreed to invest €3 billion in an entity holding Bayer's long-acting reversible contraceptives business, while Bayer retained majority ownership and control. The U.S. glyphosate business is being consolidated into a distinct entity named Ruveon.
Where Bayer fits now
Bayer occupies a rare middle ground. It is broader than a focused biotechnology company, more biologically concentrated than a traditional industrial conglomerate and more vertically integrated in agriculture than many crop-input competitors. For customers, that can mean a partner able to supply a therapy, a diagnostic workflow or an integrated set of farm tools. For investors, it means judging several innovation portfolios alongside legal and capital-structure risk.
The operational evidence is mixed but moving. Bayer reported second-quarter 2026 sales of €10.872 billion, up 2.2 percent after adjusting for currency and portfolio effects, and confirmed its currency-adjusted full-year outlook. Crop Science delivered higher sales and earnings, Pharmaceuticals held sales roughly level, and Consumer Health edged forward on sales while earnings declined. This is not a clean victory lap. It is the picture Anderson himself has described: progress inside a turnaround that remains unfinished.
The most revealing Bayer products may be those that cross old boundaries. AI now helps search chemical space for medicines and crop protection. Satellite data turns a field into a stream of decisions. Biologicals aim to replace or complement synthetic inputs. Cell and gene therapies pursue effects beyond daily symptom control. These projects do not make the three divisions identical, but they give the company reusable capabilities in data, molecular design, trials, regulation and manufacturing.
Bayer began in 1863 with synthetic dyes, molecules valued because they produced a better color. The company that followed learned to make value from molecules in much more consequential settings. Today its problem is not finding a grand theme. Health and food are durable markets, and biology is a credible connective tissue. The challenge is converting scope into speed while paying for yesterday's decisions. Keep the three clocks synchronized, and Bayer's breadth looks like an engine. Let one fall behind, and the wall starts to feel crowded.